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109 Aerosol characteristics of hypertonic saline (HS) nebulised by
the eFlow® rapid
E. Bitterle1, A. Luithlen1, K. Reul1, D. Mueller1, M. Keller1. 1Pari Pharma
GmbH, Munich, Germany
Introduction: Inhaled hypertonic saline (HS) has been proven to be tolerable and
effective for sputum induction and mucociliary clearance in CF patients (Donaldson
et al., NEJM 2006, 354(3):241−50; Elkins et al., Pediatric Pulmonology, 2006,
suppl. 28: 292).
This in-vitro study was conducted to assess the aerosol characteristics of eFlow®
rapid upon nebulisation of 4ml HS 6% available as a preservative single unit dose
vial (MucoClear® 6%).
Methods: Aerosol delivery performance was assessed by breath simulation tests
using a standardised adult breathing manoeuvre (500ml TV, 15 bpm, inh.:exh. ra-
tio = 1:1). NaCl collected on inspiratory ﬁlters was quantiﬁed by potentiometric
titration and represents the delivered dose (DD). The respirable dose (RD) corre-
sponding to NaCl in droplets <5mm was calculated based on droplet size assessment
obtained from laser diffraction tests at a continuous ﬂow of 15 L/min. Results
represent the data from 3 devices tested in duplicate, each (n = 6).
Results: The respirable fraction was 64.3%±2.6% for droplets <5mm and
30.4%±4.1% for droplets <3.3mm characterised by a mass median diameter
(MMD) of 4.2±0.2mm. 3.6±0.7min were needed to deliver a dose of 38.9±5.7%
(= 91.8±13.4mg NaCl) corresponding to a respirable dose of 25.0±3.7%
(= 59.0±8.6mg) NaCl in droplets <5mm. The high output efﬁcacy of eFlow®
rapid is apparent from a total output rate of 821±187mg/min.
Conclusions: The clinical effects of HS 6% reported by Elkins et al. are supported
by these in-vitro data indicating good lung deposition of MucoClear® 6% when
nebulised by the eFlow® rapid.
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Introduction: A new model of the eFlow® Electronic Nebulizer has been developed
with a handset that can be customized for use with speciﬁc drugs. Customizing the
handset allows optimization of the aerosol characteristics to maximize drug delivery
and minimize treatment duration. The electronic control unit (CU) can be modiﬁed
to include features like a display, which make the device more user friendly. It
would be advantageous if handsets were compatible with existing base units such
as the eFlow® rapid.
This study characterizes the aerosol output of a handset customized for aztreonam
lysine for inhalation (AZLI) in combination with the control units type 178 (for
eFlow rapid), type 678 (new CU with display) and type 078 (used in the AZLI
clinical trials).
Method: Five handsets for use with AZLI were combined with ﬁve control units
each of type 178, 678 and 078 and characterized (n = 10). Isotonic saline was used
as test substance. The characterization was conducted by laser diffractometry using
a Malvern Mastersizer X. Test conditions were controlled at 23±1 ºC, 50±5%
relative humidity and 20±1 L/min continuous ﬂow through the nebulizer.
Results: Average values for the Mass Median Diameter (MMD) were
4.34±0.15mm, 4.41±0.14mm and 4.42±0.20mm for control unit type 078, 678 and
178, respectively. Average Respirable Fractions (RF, mass % in droplets <5mm)
were 62.12±3.37%, 60.64±3.38% and 60.29±4.70% for CU type 078, 678 and
178, respectively. Considering the error of the experiment, there was no difference
between the results obtained from the different types of CU.
Conclusion: Three different types of control unit were investigated for use with
a handset customized for delivering AZLI. Aerosol characteristics of the eFlow®
Electronic Nebulizer handset for AZLI were unchanged with the use of different
types of control unit.
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Prognosis for patients with CF is improving though advanced lung disease remains
the cause of premature mortality. Lung transplantation offers patients with CF a
10-year survival of over 50% at this centre.
Hypothesis: Intensive CF therapy has led to a change in demographics of patients
referred for transplantation.
Method: Retrospective comparison of two cohorts in 1999 (n = 48) and 2007
(n = 38).
Results: The mean age in the 2007 cohort was greater at 30.3 years (range 16−57
years), vs. 1999 grp; mean age 26.3 years (16−51); though not signiﬁcant p = 0.055.
No signiﬁcant differences in lung function were noted; mean FEV1 in 1999, 25.2%
pred; range 11−47% vs. mean FEV1% pred 2007 24.9%; 10−42%; (p = 0.85). No
difference in oxygenation (1999 grp. mean pa02 9.2 kPa (range 6.7−14 kPa) vs.
2007 grp 8.2 kPa (5.7−11.1 kPa); p = 0.10). Similar levels of osteoporosis were seen
with 58.3% vs 55.2% (p = 0.94) and CF related diabetes (CFRD) rates of 35.4%
vs 28.9%; p = 0.68. The 2007 grp. had better nutritional status; mean BMI was
20.7 kg/m2 (range16−30) vs. 18.8 (13−24); p = 0.002. The EDTA-GFR was lower
in the 2007 grp (mean 104mls/min; range 39–154 vs 1999 grp. 137mls/min; 82–
188; p< 0.0001). Six minute walk test distance (6MWT) was 370m compared to
470m in 1999; p = 0.003.
Conclusions: The later cohort was older and had better nutritional status. The
number of patients with osteoporosis was unchanged. Spirometry was equivalent
but exercise tolerance as assessed by 6MWT was less. Renal function was worse,
a possible effect of repeated exposure to aminoglycosides.
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Cystic ﬁbrosis (CF) patients and CF mice display increased arachidonic acid
(AA) and decreased docosahexaenoic acid (DHA). Increased AA contributes to
the inﬂammatory state of CF patients. DHA is an anti-inﬂammatory which could
limit the effects of AA. Recently we published that CF patients and CF mice have
defects in ceramide, another phospholipid. Fenretinide (a semi-synthetic retinoid)
was able to correct ceramide in CF mice leading to an improved clearance of lung
infection. Here, we report the effects of fenretinide on AA and DHA in CF mice.
We investigate the relationship between ceramide, AA, DHA and the severity of
disease in CF patients based on the age at diagnosis. Following 28-day treatment
with fenretinide (5mg/kg/day), levels of ceramide, AA and DHA were analyzed in
CF mice (n = 19 to 22) and WT controls (n = 18 to 22) from plasma, lungs, ileum,
pancreas and liver. The same analysis was performed in plasma from 58 adult CF
patients and 72 healthy controls. Ceramide was analyzed by TLC/ELISA, and AA
and DHA by TLC and GC/MS. Treatment of CF mice with fenretinide normalized
AA and DHA in plasma and in CF affected organs. Low ceramide correlated with
elevated AA and reduced DHA in CF patients.
Analysis of late vs. early (<18) diagnosed patients demonstrate signiﬁcant differ-
ences in AA, FEV1% and pancreatic status. We propose that fenretinide treatment
could improve the biological imbalances seen in CF patients leading to clinical
improvements in CF.
